Neostigminemethylsulfaat Cf (Neostigmine Methylsulfate)

Neostigmine methylsulfate reversibly blocks acetylcholinesterase, the enzyme that breaks down acetylcholine. By preventing this breakdown, acetylcholine levels rise at nerve endings, leading to stronger stimulation of muscle and smooth‑muscle receptors, which restores muscle strength and promotes gastrointestinal motility.

The appropriate dose of Neostigminemethylsulfaat Cf is determined by the prescribing clinician based on the patient’s condition, age, weight, renal function and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

The safety of neostigmine methylsulfate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Neostigmine is a short‑acting, reversible acetylcholinesterase inhibitor commonly used for acute neuromuscular and gastrointestinal indications. Compared with longer‑acting agents such as pyridostigmine, neostigmine has a quicker onset and shorter duration, making it suitable for peri‑operative or hospital‑based use where rapid titration is needed.

Neostigminemethylsulfaat Cf should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability.

The product is supplied as a sterile injectable solution and may be given intramuscularly, intravenously, or subcutaneously according to the prescriber’s direction. Administration techniques follow standard aseptic procedures and dosing guidelines provided by the healthcare professional.

Serious risks include cholinergic crisis leading to severe muscle weakness and respiratory failure, marked bradycardia or heart block, bronchospasm in patients with reactive airway disease, and rare anaphylactic reactions. Prompt medical attention is required if any of these events occur.

Neostigminemethylsulfaat Cf is contraindicated in patients with known hypersensitivity to neostigmine or any formulation excipients, in those with mechanical intestinal obstruction, and in individuals with severe asthma or chronic obstructive pulmonary disease where bronchospasm could be life‑threatening.